Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT00862914
First received: March 16, 2009
Last updated: October 15, 2012
Last verified: October 2012
  Purpose

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.


Condition
Naevi
Malignant Melanoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

Paraffin embedded melanocytic skin lesion


Enrollment: 30
Study Start Date: July 2008
Study Completion Date: March 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
benign melanocytic naevi
2
dysplastic melanocytic naevi
3
cutaneous malignant melanoma

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

dermatologic primary care clinic

Criteria

Inclusion Criteria:

  • Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients with other forms of cancer in previous medical history
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00862914

Locations
Germany
Department of Dermatology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Principal Investigator: Prof. Dr. Peter Altmeyer Department of Dermatology and Allergology, Ruhr-University Bochum
Study Director: PD Dr. Falk G. Bechara Department of Dermatology and Allergology, Ruhr-University Bochum
  More Information

Publications:
Responsible Party: Michael Sand, Dr., Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT00862914     History of Changes
Other Study ID Numbers: 006
Study First Received: March 16, 2009
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by Ruhr University of Bochum:
Skin
MicroRNA
miRNA
Dicer
Malignant Melanoma

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on October 23, 2014